Dataset: Transcription profiling by array of human peripheral blood mononuclear cells from patients with epilepsy over a time course of dexamethasone treatment
Article title: Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced...
Article title: Expression, regulation and function of phosphofructo-kinase/fructose-biphosphatases (PFKFBs) in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia cells. Glucocorticoids (GCs) cause apoptosis and cell cycle arrest in lymphoid cells and constitute a central component in the therapy of lymphoid malignancies, most notably childhood acute lymphoblastic leukemia (ALL). PFKFB2 (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-2), a kinase controlling glucose metabolism, was identified by us previously as a GC response gene in expression profiling analyses performed in children with ALL during initial systemic GC mono-therapy. Since deregulation of glucose metabolism has been implicated in apoptosis induction, this gene and its relatives PFKFB1, 3, and 4 were further analyzed. Expression analyses in additional ALL children, non-leukemic individuals and leukemic cell lines confirmed frequent PFKFB2 induction by GC in most systems sensitive to GC-induced apoptosis, particularly in T-ALL cells. The 3 other family members, in contrast, were not or weakly expressed (PFKFB1 and 4) or not induced by GC (PFKFB3). Conditional PFKFB2 over-expression in the CCRF-CEM T-ALL in vitro model revealed that its 2 splice variants (15A and 15B) did not have any detectable effect on survival or cell cycle progression. Moreover, neither PFKFB2 splice variant significantly affected sensitivity to, or kinetics of, GC-induced apoptosis. Our data suggest that, at least in the model system investigated, PFKFB2 is not an essential upstream regulator of the anti-leukemic effects of GC. Gene expression profiles of 4 non-leukemic individuals (1 healthy and 3 with epilepsy) were generated from mononuclear cells isolated from peripheral blood samples before, and after 2, 6, and 24 hours of in-vivo glucocorticoid treatment.
- Species:
- human
- Samples:
- 16
- Source:
- E-GEOD-22779
- PubMed:
- 21092265
- Updated:
- Dec.12, 2014
- Registered:
- Sep.15, 2014
Sample | disease state | clinical treatment | time |
---|---|---|---|
GSM56324 | epilepsy | none | 0 |
GSM563242 | epilepsy | dexamethosone | 2 |
GSM563243 | epilepsy | dexamethosone | 6 |
GSM563244 | epilepsy | dexamethosone | 24 |
GSM56324 | epilepsy | none | 0 |
GSM563242 | epilepsy | dexamethosone | 2 |
GSM563243 | epilepsy | dexamethosone | 6 |
GSM563244 | epilepsy | dexamethosone | 24 |
GSM56324 | epilepsy | none | 0 |
GSM563242 | epilepsy | dexamethosone | 2 |
GSM563243 | epilepsy | dexamethosone | 6 |
GSM563244 | epilepsy | dexamethosone | 24 |
GSM563253 | normal | none | 0 |
GSM563254 | normal | dexamethosone | 2 |
GSM563255 | normal | dexamethosone | 6 |
GSM563256 | normal | dexamethosone | 24 |